Hypoglycemic Potential of Current and Emerging Pharmacotherapies in Type 2 Diabetes Mellitus

References

• . Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998;352(9131):837–853
   PubMed Web of Science ®Google Scholar
• . Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998;352(9131):854–865
   PubMed Web of Science ®Google Scholar
• . Stratton IM, Adler AI, Neil HA, . Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000;321 (7258):405–412
   PubMed Web of Science ®Google Scholar
• . Cryer PE. The barrier of hypoglycemia in diabetes. Diabetes. 2008;57(12):3169–3176
   PubMed Web of Science ®Google Scholar
• . Maynard GA, Huynh MP, Renvall M. Iatrogenic inpatient hypoglycemia: risk factors, treatment, and prevention. Analysis of current practice at an academic medical center with implications for improvement efforts. Diabetes Spectrum. 2008;21(4):241–247
   Google Scholar
• . Derr RL, Sivanandy MS, Bronich—Hall L, Rodriguez A. Insulin-related knowledge among health care professionals in internal medicine. Diabetes Spectrum. 2007;20(3):177–185
   Google Scholar
• . Beckman JA, Creager MA, Libby P. Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. JAMA. 2002; 287(19):2570–2581
   PubMed Web of Science ®Google Scholar
• . Novak V, Last D, Alsop DC, . Cerebral blood flow velocity and periventricular white matter hyperintensities in type 2 diabetes. Diabetes Care. 2006;29(7):1529–1534
   PubMed Web of Science ®Google Scholar
• . Di Carli MF, Janisse J, Grunberger G, Ager J. Role of chronic hyperglycemia in the pathogenesis of coronary microvascular dysfunction in diabetes. J Am Coll Cardiol. 2003;41(8):1387–1393
   PubMed Web of Science ®Google Scholar
• . Amiel SA, Dixon T, Mann R, Jameson K. Hypoglycaemia in type 2 diabetes. Diabet Med. 2008;25(3):245–254
   PubMed Web of Science ®Google Scholar
• . Miller CD, Phillips LS, Ziemer DC, Gallina DL, Cook CB, El—Kebbi IM. Hypoglycemia in patients with type 2 diabetes mellitus. Arch Intern Med. 2001;161(13):1653–1659
   PubMedGoogle Scholar
• . Chico A, Vidal—Ríos P, Subirà M, Novials A. The continuous glucose monitoring system is useful for detecting unrecognized hypoglycemias in patients with type 1 and type 2 diabetes but is not better than frequent capillary glucose measurements for improving metabolic control. Diabetes Care. 2003;26(4):1153–1157
   PubMed Web of Science ®Google Scholar
• . Weber KK, Lohmann T, Busch K, Donati—Hirsch I, Riel R. High frequency of unrecognized hypoglycaemias in patients with type 2 diabetes is discovered by continuous glucose monitoring. Exp Clin Endocrinol Diabetes. 2007;115(8):491–494
   PubMedGoogle Scholar
• . UK Hypoglycaemia Study Group. Risk of hypoglycaemia in types 1 and 2 diabetes: effects of treatment modalities and their duration. Diabetologia. 2007;50(6):1140–1147
   PubMed Web of Science ®Google Scholar
• . Leese GP, Wang J, Broomhall J, ; DARTS/MEMO Collaboration. Frequency of severe hypoglycemia requiring emergency treatment in type 1 and type 2 diabetes: a population-based study of health service resource use. Diabetes Care. 2003;26(4):1176–1180
   PubMed Web of Science ®Google Scholar
• . Quality of life in type 2 diabetic patients is affected by complications but not by intensive policies to improve blood glucose or blood pressure control (UKPDS 37). U.K. Prospective Diabetes Study Group. Diabetes Care. 1999;22(7):1125–1136
   PubMed Web of Science ®Google Scholar
• . Leiter LA, Yale JF, Chiasson JL, Harris SB, Kleinstiver P, Sauriol L. Assessment of the impact of fear of hypoglycemic episodes on glycemic and hypoglycemia management. Can J Diabetes. 2005;29: 186–192
   Google Scholar
• . Barnett AH, Cradock S, Fisher M, Hall G, Hughes E, Middleton A. Key considerations around the risks and consequences of hypoglycaemia in people with type 2 diabetes. Int J Clin Pract. 2010;64(8):1121–1129
   PubMed Web of Science ®Google Scholar
• . Lorber D, Anderson J, Arent S, ; American Diabetes Association. Diabetes and driving. Diabetes Care. 2012;35( suppl 1):S81–S86
   PubMedGoogle Scholar
• . Whitmer RA, Karter AJ, Yaffe K, Quesenberry CP Jr, Selby JV. Hypoglycemic episodes and risk of dementia in older patients with type 2 diabetes mellitus. JAMA. 2009;301(15):1565–1572
   PubMed Web of Science ®Google Scholar
• . Zoungas S, Patel A, Chalmers J, ; ADVANCE Collaborative Group. Severe hypoglycemia and risks of vascular events and death. N Engl J Med. 2010;363(15):1410–1418
   PubMed Web of Science ®Google Scholar
• . Bonds DE, Miller ME, Bergenstal RM, . The association between symptomatic, severe hypoglycaemia and mortality in type 2 diabetes: retrospective epidemiological analysis of the ACCORD study. BMJ. 2010;340:b4909
   PubMed Web of Science ®Google Scholar
• . Johnston SS, Conner C, Aagren M, Smith DM, Bouchard J, Brett J. Evidence linking hypoglycemic events to an increased risk of acute cardiovascular events in patients with type 2 diabetes. Diabetes Care. 2011;34(5):1164–1170
   PubMedGoogle Scholar
• . Ginde AA, Espinola JA, Camargo CA Jr. Trends and disparities in U.S. emergency department visits for hypoglycemia, 1993–2005. Diabetes Care. 2008;31(3):511–513
   PubMed Web of Science ®Google Scholar
• . Heaton A, Martin S, Brelje T. The economic effect of hypoglycemia in a health plan. Manag Care Interface. 2003;16(7):23–27
   PubMedGoogle Scholar
• . Bullano MF, Al—Zakwani IS, Fisher MD, Menditto L, Willey VJ. Differences in hypoglycemia event rates and associated cost-consequence in patients initiated on long-acting and intermediate-acting insulin products. Curr Med Res Opin. 2005;21(2):291–298
   PubMed Web of Science ®Google Scholar
• . Zhang Y, Wieffer H, Modha R, Balar B, Pollack M, Krishanthy G. The burden of hypoglycemia in type 2 diabetes: a systematic review of patient and economic perspectives. J Clin Outcomes Manag. 2010;17(12):547–557
   Google Scholar
• . Nathan DM, Buse JB, Davidson MB, ; American Diabetes Association; European Association for Study of Diabetes. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2009;32(1):193–203
   PubMed Web of Science ®Google Scholar
• . Rodbard HW, Jellinger PS, Davidson JA, . Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control. Endocr Pract. 2009;15(6):540–559
   PubMed Web of Science ®Google Scholar
• . Garber AJ, King AB, Francisco AM, Endahl L, Hollander PA. Insulin degludec improves long-term glycemic control with less nocturnal hypoglycemia compared with insulin glargine: 1-year results from a randomized basal-bolus trial in people with type 2 diabetes [abstract 74-OR]. Diabetes. 2011;60( suppl 1):A20
   Google Scholar
• . Inzucchi SE. Oral antihyperglycemic therapy for type 2 diabetes: scientific review. JAMA. 2002;287(3):360–372
   PubMed Web of Science ®Google Scholar
• . Bodmer M, Meier C, Krähenbuhl S, Jick SS, Meier CR. Metformin, sulfonylureas, or other antidiabetes drugs and the risk of lactic acidosis or hypoglycemia: a nested case-control analysis. Diabetes Care. 2008;31(11):2086–2091
   PubMed Web of Science ®Google Scholar
• . Bennett WL, Maruthur NM, Singh S, . Comparative effectiveness and safety of medications for type 2 diabetes: an update including new drugs and 2-drug combinations. Ann Intern Med. 2011;154(9):602–613
   PubMed Web of Science ®Google Scholar
• . Inzucchi SE, Bergenstal RM, Buse JB, . Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2012;35(6):1364–1379
   PubMed Web of Science ®Google Scholar
• . Rodbard HW, Blonde L, Braithwaite SS, ; AACE Diabetes Mellitus Clinical Practice Guidelines Task Force. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the management of diabetes mellitus. Endocr Pract. 2007;13( suppl 1): 1–68
   PubMedGoogle Scholar
• . Amori RE, Lau J, Pittas AG. Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis. JAMA. 2007;298(2):194–206
   PubMed Web of Science ®Google Scholar
• . Garber AJ. Long-acting glucagon-like peptide 1 receptor agonists: a review of their efficacy and tolerability. Diabetes Care. 2011;34( suppl 2):S279–S284
   PubMed Web of Science ®Google Scholar
• . van de Laar FA. Alpha-glucosidase inhibitors in the early treatment of type 2 diabetes. Vasc Health Risk Manag. 2008;4(6):1189–1195
   PubMedGoogle Scholar
• . Zangeneh F, Kudva YC, Basu A. Insulin sensitizers. Mayo Clin Proc. 2003;78(4):471–479
   PubMedGoogle Scholar
• . Inzucchi SE, McGuire DK. New drugs for the treatment of diabetes: part II: incretin-based therapy and beyond. Circulation. 2008;117(4): 574–584
   PubMed Web of Science ®Google Scholar
• . Schmitz O, Brock B, Rungby J. Amylin agonists: a novel approach in the treatment of diabetes. Diabetes. 2004;53( suppl 3):S233–S238
   PubMed Web of Science ®Google Scholar
• . Handelsman Y, Mechanick JI, Blonde L, ; AACE Task Force for Developing a Diabetes Comprehensive Care Plan. American Association of Clinical Endocrinologists Medical Guidelines for clinical practice for developing a diabetes mellitus comprehensive care plan: executive summary. Endocr Pract. 2011;17(2):287–302
   PubMed Web of Science ®Google Scholar
• . Fonseca VA, Handelsman Y, Staels B. Colesevelam lowers glucose and lipid levels in type 2 diabetes: the clinical evidence. Diabetes Obes Metab. 2010;12(5):384–392
   PubMed Web of Science ®Google Scholar
• . Gaziano JM, Cincotta AH, O'Connor CM, . Randomized clinical trial of quick-release bromocriptine among patients with type 2 diabetes on overall safety and cardiovascular outcomes. Diabetes Care. 2010;33(7):1503–1508
   PubMed Web of Science ®Google Scholar
• . Kebede MA, Alquier T, Latour MG, Poitout V. Lipid receptors and islet function: therapeutic implications? Diabetes Obes Metab. 2009;11( suppl 4):10–20
   PubMed Web of Science ®Google Scholar
• . Burant CF, Viswanathan P, Marcinak J, . TAK-875 versus placebo or glimepiride in type 2 diabetes mellitus: a phase 2, randomised, double-blind, placebo-controlled trial. Lancet. 2012;379(9824):1403–1411
   PubMed Web of Science ®Google Scholar
• . Overton HA, Fyfe MC, Reynet C. GPR119, a novel G protein-coupled receptor target for the treatment of type 2 diabetes and obesity. Br J Pharmacol. 2008;153( suppl 1):S76–S81
   PubMed Web of Science ®Google Scholar
• . Katz LB, Gambale JJ, Rothenberg PL, . Effects of JNJ-38431055, a novel GPR119 receptor agonist, in randomized, double-blind, placebo-controlled studies in subjects with type 2 diabetes. Diabetes Obes Metab. 2012;14(8):709–716
   PubMedGoogle Scholar
• . Matschinsky FM, Magnuson MA, Zelent D, . The network of glucokinase-expressing cells in glucose homeostasis and the potential of glucokinase activators for diabetes therapy. Diabetes. 2006;55(1): 1–12
   PubMed Web of Science ®Google Scholar
• . Efanov AM, Barrett DG, Brenner MB, . A novel glucokinase activator modulates pancreatic islet and hepatocyte function. Endocrinology. 2005;146(9):3696–3701
   PubMed Web of Science ®Google Scholar
• . Bonadonna RC, Heise T, Arbet—Engels C, . Piragliatin (RO4389620), a novel glucokinase activator, lowers plasma glucose both in the postabsorptive state and after a glucose challenge in patients with type 2 diabetes mellitus: a mechanistic study. J Clin Endocrinol Metab. 2010;95(11):5028–5036
   PubMed Web of Science ®Google Scholar
• . Cooper MS, Stewart PM. 11Beta-hydroxysteroid dehydrogenase type 1 and its role in the hypothalamus-pituitary-adrenal axis, metabolic syndrome, and inflammation. J Clin Endocrinol Metab. 2009;94(12):4645–4654
   PubMedGoogle Scholar
• . Rosenstock J, Banarer S, Fonseca VA, ; INCB13739-202 Principal Investigators. The 11-beta-hydroxysteroid dehydrogenase type 1 inhibitor INCB13739 improves hyperglycemia in patients with type 2 diabetes inadequately controlled by metformin monotherapy. Diabetes Care. 2010;33(7):1516–1522
   PubMedGoogle Scholar
• . Chao EC, Henry RR. SGLT2 inhibition—a novel strategy for diabetes treatment. Nat Rev Drug Discov. 2010;9(7):551–559
   PubMed Web of Science ®Google Scholar
• . Han S, Hagan DL, Taylor JR, . Dapagliflozin, a selective SGLT2 inhibitor, improves glucose homeostasis in normal and diabetic rats. Diabetes. 2008;57(6):1723–1729
   PubMed Web of Science ®Google Scholar
• . Rossetti L, Smith D, Shulman GI, Papachristou D, DeFronzo RA. Correction of hyperglycemia with phlorizin normalizes tissue sensitivity to insulin in diabetic rats. J Clin Invest. 1987;79(5): 1510–1515
   PubMed Web of Science ®Google Scholar
• . McCrimmon RJ, Evans ML, Jacob RJ, . AICAR and phlorizin reverse the hypoglycemia-specific defect in glucagon secretion in the diabetic BB rat. Am J Physiol Endocrinol Metab. 2002;283(5): E1076–E1083
   PubMedGoogle Scholar
• . Ferrannini E, Ramos SJ, Salsali A, Tang W, List JF. Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase 3 trial. Diabetes Care. 2010;33(10):2217–2224
   PubMed Web of Science ®Google Scholar
• . Bailey CJ, Gross JL, Pieters A, Bastien A, List JF. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial. Lancet. 2010;375(9733):2223–2233
   PubMed Web of Science ®Google Scholar
• . Bolinder J, Ljunggren Ö, Kullberg J, . Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin. J Clin Endocrinol Metab. 2012;97(3): 1020–1031
   PubMed Web of Science ®Google Scholar
• . Strojek K, Yoon KH, Hruba V, Elze M, Langkilde AM, Parikh S. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride: a randomized, 24-week, double-blind, placebo-controlled trial. Diabetes Obes Metab. 2011;13(10): 928–938
   PubMed Web of Science ®Google Scholar
• . Rosenstock J, Vico M, Wei L, Salsali A, List JF. Effects of dapagliflozin, an SGLT2 inhibitor, on HbA1c, body weight, and hypoglycemia risk in patients with type 2 diabetes inadequately controlled on pioglitazone monotherapy. Diabetes Care. 2012;35(7):1473–1478
   PubMed Web of Science ®Google Scholar
• . Wilding JP, Woo V, Soler NG, ; Dapagliflozin 006 Study Group. Long-term efficacy of dapagliflozin in patients with type 2 diabetes mellitus receiving high doses of insulin: a randomized trial. Ann Intern Med. 2012;156(6):405–415
   PubMed Web of Science ®Google Scholar
• . Henry RR, Murray AV, Marmolejo MH, Hennicken D, Ptaszynska A, List JF. Dapagliflozin, metformin XR, or both: initial pharmacotherapy for type 2 diabetes, a randomised controlled trial. Int J Clin Pract. 2012;66(5):446–456
   PubMed Web of Science ®Google Scholar
• . Nauck MA, Del Prato S, Meier JJ, . Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: a randomized, 52-week, double-blind, active-controlled noninferiority trial. Diabetes Care. 2011;34(9):2015–2022
   PubMed Web of Science ®Google Scholar
• . Devineni D, Morrow L, Hompesch M, . Canagliflozin improves glycaemic control over 28 days in subjects with type 2 diabetes not optimally controlled on insulin. Diabetes Obes Metab. 2012;14(6):539–545
   PubMed Web of Science ®Google Scholar
• . Phung OJ, Scholle JM, Talwar M, Coleman CI. Effect of noninsulin antidiabetic drugs added to metformin therapy on glycemic control, weight gain, and hypoglycemia in type 2 diabetes. JAMA. 2010;303(14):1410–1418
   PubMed Web of Science ®Google Scholar
• . Cryer PE. Hypoglycemia, functional brain failure, and brain death. J Clin Invest. 2007;117(4):868–870
   PubMed Web of Science ®Google Scholar